Baxter International Inc vs Global X Uranium ETF — how do they compare? Baxter International Inc trades at $26.95 (market cap $14.27B), while Global X Uranium ETF trades at $45.39. The key difference: Baxter International Inc pays a 0.14% dividend while Global X Uranium ETF pays none, and Baxter International Inc is trading nearer its 52-week high, Global X Uranium ETF nearer its low. Which is the better fit depends on your goals.
| BAX | URA | |
|---|---|---|
Market Cap | $14.27B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $28.35 | $61.81 |
52-Week Low | $15.80 | $36.45 |
Enterprise Value | $21.79B | — |
Dividend Yield | 0.14% | — |
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $27.22, down 2.02% today, with a bullish technical signal and strong recent earnings beats. The company reported Q2 2026 EPS of $0.56, beating expectations of $0.3665, and raised full-year guidance. Despite negative net income margins and high P/E of 87.85, cash flow trends improved with 2026 net cash flow projected at $468 million. Recent news highlights a 7.4% surge on August 3, 2026, following positive quarterly results and a cash tender offer announcement.
The outlook is cautiously optimistic due to earnings momentum and raised guidance, but high valuation and persistent negative profitability pose risks. Analyst consensus is mixed with 41.67% buy ratings, a $25.43 price target, and institutional activity showing volatility. Key risks include margin pressures and debt levels, though operational improvements may support recovery.
URA, the Global X Uranium ETF, trades at $45.20, up 1.85% on the day, with a bullish technical signal from moving averages and strong buying pressure indicated by ADX. The ETF benefits from positive sentiment around nuclear energy demand driven by AI power needs and government support, including a recent $17.5 billion U.S. loan commitment for new reactors. However, RSI levels suggest potential overbought conditions near-term.
The outlook for URA is positive due to structural tailwinds in nuclear energy, but risks include ETF expense ratios and uranium price volatility. Investor sentiment is bolstered by index expansions and geopolitical deals, yet the fund lacks traditional valuation metrics as it holds diversified uranium-related equities rather than operating as a single company.
Trailing returns across standard periods
Latest headlines on both assets
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →